21^st World Hematology Congress February 20-21, 2023 Madrid, Spain

Biography:

Nikita has expertise in flow cytometry. Combined with evolutionary biology new insight has been made into the expression of CD148 and into the way in which it relates to platelet subpopulations. The work was mainly based on the Mori et al 2018.

Abstract:

Primary function of platelets is the formation of a protective barrier against blood loss. Secondary but no less important functions of platelets are tissue repair and immunity. Similar to the functioning of much of the rest of biology the exchange of phosphate groups plays a key role in the functioning of platelets. This exchange is potentiated by phosphatase and kinase enzymes. The CD148 encoded by PTPRJ is a phosphatase that is implicated both positive and negative regulation of platelet activation. Despite recent advances in understanding of CD148 the exact level of expression, structure, mechanism of action and precise role in the functioning of platelets are still not one hundred percent clear. The level of expression was the focus of the study. Finding the optimal method of visualising CD148 expression was the initial aim of the study. In the process of investigation, the varying levels of CD148 expression have pointed the researchers to the possibility that different subpopulations of platelets express CD148 at a varying level. Reticulated platelets (younger subset of the platelet population) were picked as most promising subpopulation. Syto 13 a nucleic dye was used distinguish reticulated platelets rather than a more traditional thiazole orange. The study proved successful in confirming the differences in the level of expression of CD148. Reticulated platelets were shown statistically and graphically to express more CD148 than the rest of the population (Figure 1). Suggestions for further research and modalities of possible therapies were made.

Biography:

Victor Alfred H. Catambing is a board-certified internist and is currently an adult hematology fellow-in-training from the Philippine General Hospital, Philippines. He is an enthusiastic and innovative fellow-in-training whose life-long goal is provide the best possible care to patients with hematologic conditions in distant areas of the Philippines.

Abstract:

The co-existence of myeloid and lymphoid malignancies is rare and poorly understood. It is an extremely uncommon disease reported in a very few cases. We report a rare case of multiple myeloma and chronic myelogenous leukemia co-existence in a 55-year-old male initially presenting with granulocytosis and splenomegaly. Subsequent work-up with BCR/ABL FISH assay and bone marrow aspiration and biopsy revealed chronic myelogenous leukemia. During the first 4 months of his treatment with a tyrosine kinase inhibitor, there was a note of progressive and persistent pancytopenia with increasing creatinine trends. A repeat bone marrow aspiration and biopsy supplemented with serum protein electrophoresis with immunotyping and serum free light chain assay were done demonstrating multiple myeloma. A BCR-ABL for QRT PCR was also conducted with a result of 3.81%. Hence, the diagnosis of co-existent multiple myeloma and chronic myelogenous leukemia, Triplet anti-myeloma therapy and tyrosine kinase inhibitor are given to this patient.

Multiple myeloma is the neoplastic expansion of plasma cells that produces a monoclonal immunoglobulin. It is a relatively uncommon malignancy. On the other hand, chronic myelogenous leukemia is a form of myeloproliferative neoplasm that results from abnormal production and proliferation of mature and maturing granulocytes associated with the BCR/ABL fusion gene. The abnormal cells involved in these diseases are distinctly different making its co-occurrence extremely rare. In addition, literature regarding the approach to its diagnosis, treatment and outcome is scarce. Increasing recognition and awareness of the co-existence of the two entities is a step closer to optimizing approach to its diagnosis and treatment 

Biography:

Shuchita Pathak is working as DM medical oncology resident in M S Ramaiah Medical College, Bangalore. She completed her MBBS in 2014 from GMC Haldwani Medical College in Uttrakhand. After that she completed her DNB radiation oncology post-graduation from Bhagwan Mahaveer Cancer Hospital, Jaipur. After completing her post-graduation she worked as senior resident in AIIMS New Delhi for 1 year and after that got selected for medical oncology in M S Ramaiah Medical College.

Abstract:

A 38 year old female presented in our institute with 2 months history of paraparesis with loss of sensation below umbilicus. Diagnostic workup revealed extradural mass at thoracic vertebral level 4 to 6. She underwent D3-D6 laminoplasty with excision of lesion. Histopathology report revealed Non Hodgkin lymphoma for follicular centre cell type with marginal zone transformation. On further evaluation PET-CT scan was done which confirmed localized primary extradural location of Non-Hodgkin lymphoma. She received modified R-GMALL protocol chemotherapy [Figure 1]. Her neurological condition improved at end of chemotherapy.

Biography:

Amna has done her MBBS in 2010 from Dow University of Health Sciences and FCPS (Hematology) in 2018 from Dr. Ziauddin University Hospital. Since 2018 She have been serving in the department of Hematology/Oncology diagnosing and treating a number of benign and malignant disorder including nutritional deficiencies, acute leukemia, chronic leukemia, lymphoma, hemoglobinopathy, inherited bone marrow failure syndromes, coagulopathies, transfusion related problems, thrombophilia etc. She is dealing with chemo-immuntherapies. She worked on rare blood groups. Her research is on bcr-abl positivity frequency in childhood B-ALL, GERD etc.

Abstract:

Primary myelofibrosis is a haematopoietic stem cell neoplasm resulting in ineffective haematopoiesis and bone marrow fibrosis. We present a case of a 67-year-old male patient who came to the oncology/haematology department of Dr. Ziauddin Hospital, Karachi, in February 2020 with complaints of weight loss, gastroesophageal reflux and loss of appetite. Examination revealed splenomegaly and initial workup demonstrated bicytopenia on complete blood picture. Bone marrow biopsy was consistent with pre-fibrotic myelofibrosis (Janus Kinase 2 (JAK-2) positive). He was categorized as intermediate-2 risk according to Dynamic International Prognostic Scoring System (DIPPS) with score of 3 and was advised to start JAK-1/JAK-2 inhibitors. Prior to therapy, he underwent Positron Emission Tomography-Computed Tomography (PET/CT) scan which showed increased Fluorodeoxyglucose (FDG) uptake in the spleen and bone marrow. Monitoring by the scan after initiating treatment demonstrated decreased FDG uptake in bone marrow and spleen, demonstrating that PET/CT is a non-invasive way to assess and monitor treatment response in pre-fibrotic myelofibrosis.

Biography:

Farah Aldouri is a clinical hematologist who has a great interest in hereditary hematological disorders, precisely thalassemias and bleeding disorders. She has expertise in managing and follow up of cases and works in collaboration with other specialists and other centres in Iraq in order to deliver the best to patients in the country.

Abstract:

Platelets are anucleated cellular components of blood which play a fundamental role in maintaining vascular integrity following injuries through plug formation, a process referred to as primary hemostasis. Platelet adhesion, activation, secretion and aggregation are intricately connected steps involved in the process. Once formed, support to the fresh clot is required to keep it held tight in place. A cascade of chemical interactions is ignited as a consequence to primary hemostasis, the secondary hemostasis, culminates in producing fibrin mesh which provides proper scaffolding to the newly formed plug 

Biography:

Huilin Wei has more than 15 years of extensive experience in molecular and protein assay development. She has her expertise in molecular biology, immunology and oncology. Current research focuses on assay control and detection platforms to provide accurate and high quality IVT products for cancer diagnostic and monitoring.

Abstract:

Xpert® BCR-ABL Ultra, automated cartridge-based assay for monitoring BCR-ABL transcript levels, is calibrated by WHO IS to standardize the % reporting for both b2a2/e13a2 BCR-ABL (e13a2) and b3a2/e14a2 BCR-ABL (e14a2) relative to control ABL gene in peripheral blood of patients as a standard management of Chronic Myeloid Leukemia (CML). Studies have shown differences in patients carrying e13a2 or e14a2 in molecular response to Tyrosine Kinase Inhibitor (TKI) treatment. Therefore, it is necessary to understand if there is % reporting differences between two transcripts calibrated by WHO IS and explore the calibration method using breakpoint specific RNA input Copy Number (CN) for accurate TKI treatment monitoring.

Biography:

Tran Tran has more than 15 years of extensive experience in molecular and protein assay development. Expertise in molecular biology, immunology and oncology. Current research focuses on assay control and detection platforms to provide accurate and high quality IVT products for cancer diagnostic and monitoring.

Abstract:

Xpert® BCR-ABL Ultra, automated cartridge-based assay for monitoring BCR-ABL transcript levels, is calibrated by WHO IS to standardize the % reporting for both b2a2/e13a2 BCR-ABL (e13a2) and b3a2/e14a2 BCR-ABL (e14a2) relative to control ABL gene in peripheral blood of patients as a standard management of Chronic Myeloid Leukemia (CML). Studies have shown differences in patients carrying e13a2 or e14a2 in molecular response to Tyrosine Kinase Inhibitor (TKI) treatment. Therefore, it is necessary to understand if there is % reporting differences between two transcripts calibrated by WHO IS and explore the calibration method using breakpoint specific RNA input Copy Number (CN) for accurate TKI treatment monitoring.